Compare · IDXG vs MDLN
IDXG vs MDLN
Side-by-side comparison of Interpace Biosciences, Inc. (IDXG) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXG and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN carries a market cap of $44.40B.
- MDLN has hit the wire 20 times in the past 4 weeks while IDXG has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 1 for IDXG).
- Company
- Interpace Biosciences, Inc.
- Medline Inc.
- Price
- -
- $33.80+0.58%
- Market cap
- -
- $44.40B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2025
- News (4w)
- 0
- 20
- Recent ratings
- 1
- 25
Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Latest IDXG
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Interpace Biosciences, Inc.
- Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
- Amendment: SEC Form 10-K/A filed by Interpace Biosciences, Inc.
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Interpace Biosciences, Inc.
- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
- Large owner 1315 Capital Ii, L.P. converted options into 9,405,941 shares (SEC Form 4)
- Large owner Ampersand 2018 Limited Partnership converted options into 13,861,386 shares (SEC Form 4)
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)